日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Thailand's Emerging Role in the Cell and Gene Therapy Revolution: A Review of Progress and Potential

泰国在细胞和基因治疗革命中扮演着日益重要的角色:进展与潜力回顾

Viprakasit, Vip; Tulalamba, Warut; Suksangpleng, Thidarat; Ekwattanakit, Supachai

Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare?

Luspatercept 与 mitapivat 治疗非输血依赖性 β-地中海贫血:敢于比较吗?

Musallam, Khaled M; Sheth, Sujit; Cappellini, Maria Domenica; Kuo, Kevin H M; Kattamis, Antonis; Aydinok, Yesim; Viprakasit, Vip; Taher, Ali T

Non-Transfusion-Dependent Thalassemia: An Image Gallery Worth a Thousand Words

非输血依赖型地中海贫血:一图胜千言

Musallam, Khaled M; Sheth, Sujit; Coates, Thomas D; Al-Samkari, Hanny; Cappellini, Maria Domenica; Kuo, Kevin H M; Viprakasit, Vip; Taher, Ali T

Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study

luspatercept治疗非输血依赖型β-地中海贫血的疗效和安全性:BEYOND研究的长期结果

Taher, Ali T; Viprakasit, Vip; Kattamis, Antonis; Perrotta, Silverio; Ricchi, Paolo; Porter, John B; Coates, Thomas D; Forni, Gian Luca; Musallam, Khaled M; Esposito, Oriana; Pilot, Richard; Kuo, Wen-Ling; Lai, Yinzhi; Reverte, Marta; Wei, Richard; Bueno, Luciana Moro; Cappellini, Maria Domenica

Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study

铁转运蛋白抑制剂vamifeport在非输血依赖型β-地中海贫血患者中的安全性和药效学:一项随机2a期研究的结果

Kattamis, Antonis; Taher, Ali; Viprakasit, Vip; Levin, Carina; Hermosilla, Ricardo; Szecsödy, Peter; Richard, Frank; Cappellini, M Domenica; Porter, John

Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion-Dependent Thalassemia Identified Using Whole-Genome Sequencing

利用全基因组测序鉴定输血依赖型地中海贫血患者对去铁酮反应的药物基因组学和临床预测因子

Yampayon, Kittika; Sakares, Watchara; Pitinanon, Krittin; Limwongse, Chanin; Srichairatanakool, Somdet; Koonyosying, Pimpisid; Sukasem, Chonlaphat; Triparn, Kwankom; Piriyapongsa, Jittima; Ekwattanakit, Supachai; Viprakasit, Vip; Yodsurang, Varalee

Bridging Pharmacokinetics and Pharmacodynamics: A PBPK/PD Model-Based Approach for Deferasirox Dosing in Transfusion-Dependent Thalassemia

连接药代动力学和药效学:基于PBPK/PD模型的去铁酮在输血依赖型地中海贫血患者中的给药策略

Sakares, Watchara; Udomnilobol, Udomsak; Pan, Xian; Yampayon, Kittika; Ekwattanakit, Supachai; Viprakasit, Vip; Limwongse, Chanin; Srichairatanakool, Somdet; Teerawonganan, Polsak; Kunsa-Ngiem, Sumate; Khaowroongrueng, Vipada; Techatanawat, Isariya; Prueksaritanont, Thomayant; Yodsurang, Varalee

Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study

地拉罗司颗粒剂和分散片制剂在输血性铁过载患儿中的依从性和临床获益:一项随机、开放标签、多中心 II 期研究

Taher, Ali T; Wali, Yasser; Cruz, Maria Cecilia; Charoenkwan, Pimlak; Aydinok, Yesim; Werner, Olena; Govindaraju, Sameera; Romen, Fabian; Viprakasit, Vip

Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment

长期服用米塔匹伐治疗的丙酮酸激酶缺乏症成年患者的骨矿物质密度

Al-Samkari, Hanny; Grace, Rachael F; Glenthøj, Andreas; Andres, Oliver; Barcellini, Wilma; Galacteros, Frédéric; Kuo, Kevin H M; Layton, D Mark; Morado, Marta; Viprakasit, Vip; Tai, Feng; Urbstonaitis, Rolandas; Morales, Jaime; McGee, Bryan; Beers, Eduard J van

Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial

确定 NTDT-PRO 评分改善的阈值,以支持对非输血依赖型 β-地中海贫血患者临床研究中治疗获益的结论:一项 2 期双盲、安慰剂对照、随机试验的汇总数据分析

Taher, Ali T; Musallam, Khaled M; Viprakasit, Vip; Kattamis, Antonis; Lord-Bessen, Jennifer; Yucel, Aylin; Guo, Shien; Pelligra, Christopher G; Shields, Alan L; Shetty, Jeevan K; Glassberg, Mrudula B; Bueno, Luciana Moro; Cappellini, Maria Domenica